Cargando…

Microenvironment-Dependent Phenotypic Changes in a SCID Mouse Model for Malignant Mesothelioma

Background and Aims: Malignant mesothelioma is an aggressive, therapy-resistant tumor. Mesothelioma cells may assume an epithelioid or a sarcomatoid phenotype, and presence of sarcomatoid cells predicts poor prognosis. In this study, we investigated differentiation of mesothelioma cells in a xenogra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Darai-Ramqvist, Eva, Nilsonne, Gustav, Flores-Staino, Carmen, Hjerpe, Anders, Dobra, Katalin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3739415/ https://www.ncbi.nlm.nih.gov/pubmed/23951555 http://dx.doi.org/10.3389/fonc.2013.00203

Ejemplares similares

Variation in Drug Sensitivity of Malignant Mesothelioma Cell Lines with Substantial Effects of Selenite and Bortezomib, Highlights Need for Individualized Therapy
por: Szulkin, Adam, et al.
Publicado: (2013)

Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2013)

Integrative approach to cytologic and molecular diagnosis of malignant pleural mesothelioma
por: Hjerpe, Anders, et al.
Publicado: (2020)

Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
por: Mundt, Filip, et al.
Publicado: (2014)

Inhibitors of cytoskeletal dynamics in malignant mesothelioma
por: Reis, Katarina, et al.
Publicado: (2020)

Cytoskeletal Organization Correlates to Motility and Invasiveness of Malignant Mesothelioma Cells
por: Keller, Maureen, et al.
Publicado: (2021)

Phenotype-dependent apoptosis signalling in mesothelioma cells after selenite exposure
por: Nilsonne, Gustav, et al.
Publicado: (2009)

Novel Genes and Pathways Modulated by Syndecan-1: Implications for the Proliferation and Cell-Cycle Regulation of Malignant Mesothelioma Cells
por: Szatmári, Tünde, et al.
Publicado: (2012)

Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions
por: Szulkin, Adam, et al.
Publicado: (2014)

Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma
por: Wadowski, Benjamin, et al.
Publicado: (2021)

Proteome Screening of Pleural Effusions Identifies Galectin 1 as a Diagnostic Biomarker and Highlights Several Prognostic Biomarkers for Malignant Mesothelioma
por: Mundt, Filip, et al.
Publicado: (2014)

Mapping the Interactome of the Nuclear Heparan Sulfate Proteoglycan Syndecan-1 in Mesothelioma Cells
por: Kumar-Singh, Ashish, et al.
Publicado: (2020)

P14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
por: Pezzuto, Federica, et al.
Publicado: (2021)

Syndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
por: Javadi, Joman, et al.
Publicado: (2021)

Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma
por: Xu, Xiaoling, et al.
Publicado: (2020)

Multiplex Soluble Biomarker Analysis from Pleural Effusion
por: Javadi, Joman, et al.
Publicado: (2020)

Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
por: Hjerpe, Anders, et al.
Publicado: (2015)

The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy
por: Chu, Gerard J., et al.
Publicado: (2019)

Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

Prognostic Role of Tumor Immune Microenvironment in Pleural Epithelioid Mesothelioma
por: Ollila, Hely, et al.
Publicado: (2022)

Syndecan-1 in Cancer: Implications for Cell Signaling, Differentiation, and Prognostication
por: Szatmári, Tünde, et al.
Publicado: (2015)

Preclinical Models of Malignant Mesothelioma
por: Testa, Joseph R., et al.
Publicado: (2020)

Immunotherapy in Malignant Pleural Mesothelioma
por: de Gooijer, Cornedine J., et al.
Publicado: (2020)

Utility of BerEp4/calretinin and desmin/epithelial membrane antigen (EMA) dual immunocytochemical staining in effusion cytology
por: Hjerpe, Anders, et al.
Publicado: (2022)

Editorial: Emerging Therapies for Malignant Mesothelioma
por: van Zandwijk, Nico, et al.
Publicado: (2020)

Unraveling tumor microenvironment heterogeneity in malignant pleural mesothelioma identifies biologically distinct immune subtypes enabling prognosis determination
por: Yang, Kaidi, et al.
Publicado: (2022)

The Biology of Malignant Mesothelioma and the Relevance of Preclinical Models
por: Blanquart, Christophe, et al.
Publicado: (2020)

Mesothelioma Malignancy and the Microenvironment: Molecular Mechanisms
por: Cersosimo, Francesca, et al.
Publicado: (2021)

The Role of Syndecan-1 in Cellular Signaling and its Effects on Heparan Sulfate Biosynthesis in Mesenchymal Tumors
por: Szatmári, Tünde, et al.
Publicado: (2013)

Ex vivo evaluation of tumor cell specific drug responses in malignant pleural effusions
por: Hillerdal, Carl-Olof, et al.
Publicado: (2017)

New Perspectives on Diagnosis and Therapy of Malignant Pleural Mesothelioma
por: Rossini, Marika, et al.
Publicado: (2018)

Real-World Diagnostic Accuracy and Use of Immunohistochemical Markers in Lung Cancer Diagnostics
por: Ericson Lindquist, Kajsa, et al.
Publicado: (2021)

Development and Validation of a Prognostic Signature for Malignant Pleural Mesothelioma
por: Zhou, Jian-Guo, et al.
Publicado: (2019)

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
por: Cantini, Luca, et al.
Publicado: (2020)

Case report: Rare intrapulmonary malignant mesothelioma complicated with myositis
por: Gong, Dandan, et al.
Publicado: (2022)

Liquid Biopsy in Malignant Pleural Mesothelioma: State of the Art, Pitfalls, and Perspectives
por: Cavallari, Ilaria, et al.
Publicado: (2019)

Cellular Immunotherapy and Locoregional Administration of CAR T-Cells in Malignant Pleural Mesothelioma
por: Belderbos, Robert A., et al.
Publicado: (2020)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Aurora Kinase A as a Diagnostic and Prognostic Marker of Malignant Mesothelioma
por: Guo, Zhenying, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma Epidemiology in the United States From 2000 to 2016
por: Thomas, Akesh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pamg6iu5pgc5h3ihj3842784lk